LETTERS

Serpiginous choroidopathy presenting as choroidal neovascularisation

Serpiginous choroidopathy is an insidious, relentlessly progressive, idiopathic inflammatory disease affecting the retinal pigment epithelium and inner choroid. Choroidal neovascularisation (CNV) is a well recognised late complication of serpiginous choroidopathy in 10–25% of affected patients. In all previously reported cases CNV was recognised at the time of or after the diagnosis of serpiginous choroidopathy was established. We report a patient presenting with CNV who subsequently developed clinical findings characteristic of serpiginous choroidopathy.

Case report

A 31 year old man presented with decreased vision in his right eye in July 1997. Examination revealed acuities of 20/40 right eye and 20/20 left eye with normal anterior segments. The right fundus showed subretinal fluid and haemorrhage adjacent to the disc (Fig 1A). The left eye showed an irregularity superior to the optic disc (Fig 1B). Fluorescein angiography (Fig 2A, B) revealed peripapillary choroidal neovascular membranes in both eyes that were treated with argon laser photocoagulation. In April 1998 and February 1999 the left eye required photocoagulation for recurrent peripapillary CNV. Evaluation for floaters in February 2000 revealed 1+ vitreous cells and new lesions in the left eye.

Examination at the National Eye Institute in April 2000 revealed acuities of 20/40 right eye and 20/16 left eye with normal anterior segments. The vitreous contained trace cells without haze bilaterally. The right fundus showed a large peripapillary chorioretinal scar. The left fundus revealed a chorioretinal scar superior to the disc and two yellow, irregularly circumscribed, deep macular lesions (Fig 3A, B). The retinal vessels and discs were normal and no subretinal fluid, haemorrhage, or macular oedema was noted in either eye.

Fluorescein angiography revealed early hypofluorescence and late hyperfluorescence corresponding to the macular lesions in the left eye (Fig 3C, D) with no evidence of CNV in either eye. Laboratory studies were non-diagnostic. A diagnosis of serpiginous choroidopathy was made based on the clinical and fluorescein characteristics of the macular lesions in the left eye.

Comment

CNV in serpiginous choroidopathy is associated with a poor visual prognosis. In a small study CNV was reported to develop within 16 months of the serpiginous diagnosis. In a larger retrospective study of 53 serpiginous patients active CNV was found in three patients at the time of initial diagnosis and in three others within 2–17 months. Our patient differs from those previously reported in that he was diagnosed and treated for idiopathic CNV before the recognition of clinical findings.
diagnostic of serpiginous choroidopathy. Other causes of posterior uveitis associated with CNV and choroidal lesions similar to those seen in our patient include acute posterior multifocal placoid plaque-like retinopathy (APMPPE), presumed ocular histoplasmosis syndrome (POHS), sarcoidosis, multifocal choroiditis, birdshot chorioretinopathy, and toxoplasmosis. As with most cases of serpiginous choroidopathy, the CNV in these entities typically occurs late in the disease course.

The exact pathogenesis of idiopathic CNV is unknown. CNV in eyes with uveitis, however, is believed to develop in direct response to the disease course. The balance between vascular growth factors, such as vascular endothelial growth factor (VEGF), and inhibitors, is believed to develop in direct response to the disease course.

In the early stages of development active serpiginous lesions and CNV may appear as poorly defined subretinal lesions difficult to differentiate by ophthalmoscopy. Typically with fluorescein angiography classic CNV and serpiginous lesions are readily distinguished as the former shows early hyperfluorescence which is not masked by the latter characteristic shows early blockage. Occult CNV, which may show subtle or less pronounced early hyperfluorescence with late leakage, however, may be more difficult to distinguish from an early serpiginous lesion.

This case illustrates that serpiginous choroidopathy may present with CNV. In contrast to idiopathic CNV, optimal treatment of CNV in patients with uveitis may require immunosuppressive treatment that addresses the underlying ocular inflammation with or without adjunctive laser therapy. Further investigation is needed to better define the role of emerging therapies for CNV such as photodynamic therapy which may offer promise for the treatment of CNV in uveitis patients.

Financial support: none.

D K Lee
Department of Ophthalmology, Jonas Friedenwald Ophthalmic Institute at Maryland General Hospital, Baltimore, MD, USA

W Augustin, R B Buggage, E B Suhler Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Correspondence to: Ronald R Buggage, MD, National Eye Institute, National Institutes of Health, Bldg 10, Room 101N112, Bethesda, MD 20892–1857, USA; BuggageR@nieh.nih.gov

Accepted for publication 30 October 2002

References
of typical MFS. The delayed P100 latency in her VEP also provides electrophysiological evidence that the optic nerve is affected in anti-GQ1b antibody positive MFS. Furthermore, this is the first documented case known to the author of optic neuritis in the recurrent subtype of MFS which is associated with a higher frequency of the HLA-DR2 allele.

J W Chan
Department of Internal Medicine, Division of
Neurology, University of Nevada School of
Medicine, Las Vegas, Nevada 89102, USA; worjun@aol.com

Accepted for publication 6 January 2003

References

Ocular myasthenia gravis and inflammatory bowel disease: a case report and literature review

Myasthenia gravis has been reported to be associated with both ulcerative colitis (UC) and Crohn’s disease (CD).1–3 The link between inflammatory bowel disease (IBD) and myasthenia gravis (MG) is thought to be related to the production of autoantibodies.4

Myasthenia gravis is also associated with other autoimmune diseases including alopecia, lichen planus, vitiligo, and systemic lupus erythematosus.4

Similarly, IBD frequently presents with other autoimmune disorders. One study demonstrated a 9.4% prevalence of autoimmune disorders in patients with UC including sclerosing cholangitis, thyroid disorders, vitiligo, insulin dependent diabetes mellitus, thyroid disease, pernicious anaemia, scurvy, and seropositive rheumatoid arthritis.4,5 Despite the association between MG and other autoimmune disorders, there are relatively few reports of ocular findings as the presenting sign of MG in patients with IBD.

Case report
A 21 year old African-American male, with a medical history of biopsy proved ulcerative colitis diagnosed in 1995, focal segmental glomerular sclerosis determined by renal biopsy in 1995, and primary sclerosing cholangitis determined by liver biopsy in 2000 presented to the neuro-ophthalmology service with complaints of binocular diplopia and ptosis of the left upper eyelid. Both the diplopia and the ptosis were better in the morning and worsened during the course of the day. His ulcerative colitis had been in remission for the past 3 years without medication.

Best corrected visual acuity was 20/25 in each eye. The external examination revealed ptosis of the left upper eyelid that worsened in sustained upgaze. He had limited extraocular motility in all fields of gaze (Fig 1). The remainder of the neuro-ophtalmic examination was normal and he had no difficulty with speech or swallowing.

Laboratory evaluation revealed a positive acetylcholine receptor antibody and normal thyroid function studies. There was no evidence of a thymic mass on magnetic resonance imaging of the chest.

The patient returned to the emergency room 1 week later with difficulty swallowing and shortness of breath. He was hospitalised for plasmapheresis and upon discharge treated with imuran, prednisone, and mestinon.

Table 1

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age (years)</th>
<th>Sex</th>
<th>IBD</th>
<th>Duration of IBD before diagnosis of MG (years)</th>
<th>AchR antibody reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miller 1971a</td>
<td>35</td>
<td>Male</td>
<td>UC</td>
<td>13</td>
<td>Unknown</td>
</tr>
<tr>
<td>Tan 1974a</td>
<td>38</td>
<td>Male</td>
<td>UC</td>
<td>12</td>
<td>Unknown</td>
</tr>
<tr>
<td>Martin et al, 1991b</td>
<td>63</td>
<td>Male</td>
<td>CD</td>
<td>15</td>
<td>Positive</td>
</tr>
<tr>
<td>Gower-Rousseau et al, 1993c</td>
<td>27</td>
<td>Female</td>
<td>UC</td>
<td>10</td>
<td>Positive</td>
</tr>
<tr>
<td>Finnie et al, 1994a</td>
<td>21</td>
<td>Female</td>
<td>CD</td>
<td>3</td>
<td>Positive</td>
</tr>
<tr>
<td>Losso et al, 1995b</td>
<td>11</td>
<td>Male</td>
<td>CD</td>
<td>9</td>
<td>Unknown</td>
</tr>
<tr>
<td>Present report</td>
<td>21</td>
<td>Male</td>
<td>UC</td>
<td>7</td>
<td>Positive</td>
</tr>
</tbody>
</table>

IBD = inflammatory bowel disease, MG = myasthenia gravis, AchR = acetylcholine receptor, UC = ulcerative colitis, CD = Crohn’s disease.

Figure 1 External photograph shows ptosis of the left upper eyelid, restriction of all extraocular movements of the left eye, and an elevation and adduction deficit of the right eye.
immature helper T cells suggesting migration without normal maturation.\textsuperscript{1,2}  
The immunological link between MG and IBD is highlighted by two reports of patients undergoing surgical treatment. One report of a patient with both MG and CD documented improvement in perineal and perianal disease following uncontrolled MG.\textsuperscript{3} Another patient with both MG and UC demonstrated regression of the myasthenia following proctectomy.\textsuperscript{4}  
Although the simultaneous occurrence of these two autoimmune disorders is uncommon, it is important to understand that occult findings may be the initial manifestation of MG in patients with IBD.

The authors have no proprietary interest in any contents of this manuscript.

R Foroozan, R Sambursky  
Neuro-Ophthalmology Service, Baylor College of Medicine, 6655 Fannin, NC-205, Houston, TX 77030, USA  
Correspondence to: Dr Rod Foroozan, Neuro-Ophthalmology Service, Baylor College of Medicine, 6655 Fannin, NC-205, Houston, TX 77030, USA  
Accepted for publication 10 January 2003

References

Magnetic resonance imaging findings in malignant melanoma of the lacrimal sac

A case of primary malignant melanoma of the lacrimal sac is presented. This is the first report of the preoperative magnetic resonance imaging (MRI) findings of malignant melanoma of the lacrimal sac.

Case report

A 54 year old Chinese woman was referred to an ophthalmologist complaining of a 6 month history of left sided bloody tears and epistaxis. She had a firm, non-tender left medial canthal swelling, and syringing revealed left nasolacrimal duct (NLD) obstruction. Ocular and periorbital examination was otherwise normal. A dacryocystogram (DCG) demonstrated a filling defect in the lacrimal sac with NLD obstruction.

An ENT opinion was sought, and nasal examination revealed left sided septal deviation, with no obvious cause for the epistaxis. Computed tomography (CT) of the head and orbits demonstrated a left lacrimal sac lesion extending into the NLD with proximal dilation of the duct and no apparent bone erosion (Fig 1A). MRI confirmed the presence of a lacrimal sac lesion with intermediate signal intensity on T1 and T2 weighted images (Fig 2A, B). The lesion enhanced with intravenous gadolinium.

An incisional biopsy of the lacrimal sac (Fig 1B) under frozen section control, and paraffin sections, confirmed malignant melanoma.

A full medical review, including MRI of the chest and abdomen, and liver function tests, excluded tumour elsewhere. However, abdominal MRI and ultrasound revealed a co-incident polycystic liver.

Three weeks after biopsy, a wide local excision including the medial upper and lower eyelids, dacryocystectomy and medial maxillectomy was performed. A tumour, confined to the sac, and invasion through the medial wall of the upper NLD, into the lateral wall of the nose, and approaching nasal septal mucosa, was seen peroperatively and confirmed histologically.

She underwent postoperative adjuvant radiation therapy (55 grays) and to date, 4 months later, remains well.

Comment

Malignant melanoma of the lacrimal sac is rare accounting for 5% of lacrimal sac tumours.\textsuperscript{5} It has an unfavourable prognosis compared with other causes of lacrimal sac tumour, and is considered more aggressive than cutaneous malignant melanoma.\textsuperscript{6} Response to treatment is generally poor, with up to 80% of cases recurring within 2 years.

Radiological features of lacrimal sac tumours include filling defects on DCG and mass lesions on CT.\textsuperscript{7} However, to the authors’ knowledge, this is the first report of the MRI findings of malignant melanoma of the lacrimal sac.

Owing to the paramagnetic properties of melanin, malignant melanoma appears hyperintense on T1 weighted imaging, and hypointense on T2 weighted imaging.\textsuperscript{8} A study of six mucosal melanomas of the head and neck found that on T1, five lesions were hyperintense and one was isointense.\textsuperscript{9} On T2, five were of mixed intensity and one was iso-intense. They concluded that hyperintensity on T1 of mucosal melanomas was characteristic but not universal.

The majority of malignant lacrimal sac tumours are epithelial in origin.\textsuperscript{10} Imaging features suggesting malignancy include invasion of bone, rapid growth, and irregular margins with skin fixation. On MRI, the majority of epithelial tumours have intermediate signal intensity on T1 and high T2 signal intensity. High tumour cellularity is associated with intermediate to low T2 signal intensity.\textsuperscript{11}

High signal intensity on T1 is not specific for malignant melanoma. Subacute haemorrhage caused by the presence of methaemoglobin is more likely and although melanoma may undergo intratumoral haemorrhage, other tumours with a tendency to bleed include small cell lung carcinoma, choriocarcinoma, and renal cell carcinoma metastases.\textsuperscript{12} Less likely causes include fat containing tumours (lipoma, dermoid, and teratoma).

Figure 1 (A) Coronal CT scan demonstrating a solid mass of the left lacrimal sac with proximal dilation of the nasolacrimal duct (arrow). (B) Incisional biopsy with lacrimal sac opened and melanoma visible.

Figure 2 (A) T1 weighted sagittal MRI demonstrating intermediate signal intensity mass lesion of the lacrimal sac and proximal nasolacrimal duct (arrow). (B) T2 weighted axial MRI demonstrating intermediate signal intensity mass lesion of the left lacrimal sac (arrow).
requiring MRI fat suppression methods, paramagnetic material (manganese, iron, and copper), and very high (non-paramagnetic) intratumoral protein concentration.

MRI has been reported as a useful investigative tool in the assessment of lacrimal disease owing to its ability to delineate soft tissues. Intravenous and intracanalicular gadolinium adds useful information on lesion enhancement and lacrimal apparatus structure and function. The predictive value of MRI for lacrimal sac melanoma, however, appears to be variable. Hyperintensity on T1 relies on the paramagnetic properties of melanin, the presence of which is variable in amelanotic melanoma. This is supported by our case, where only moderate T1 hyperintensity with contrast enhancement was demonstrated.

K Billing, R Malhotra, D Selva
Oculoplastic and Orbital Unit, Department of Ophthalmology, Royal Adelaide Hospital, The University of Adelaide, Australia
S Salonikis, J Taylor
MRI Unit, Department of Radiology, Royal Adelaide Hospital, Adelaide, Australia
S Krishnan
Department of Otolaryngology, Royal Adelaide Hospital, Adelaide, Australia

Correspondence to: Dr Dinesh Selva, Oculoplastic and Orbital Clinic, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000; Astrewoo@inhralinh.sa.gov.au

Accepted for publication 10 January 2003

References


Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery

Limited macular translocation (LMT) is one of the treatment options for subfoveal choroidal neovascularisation (CNV) resulting from pathological myopia. The fundamental surgical principle involves the transposition of the foveal neurosensory retina to a new site with more healthy underlying retinal pigment epithelium. Direct laser photoagulation is usually employed as an adjunct measure in eradicating the original CNV after the surgery. It has been observed that geometrically sizeable translocation is a prerequisite for a long term surgical success. The degree of translocation is, however, not often predictable and any ineffective displacement may render the subsequent laser photoagulation extremely difficult or even impossible to perform. As a result, the recurrent or persistent CNV intruding the newly relocated fovea may jeopardise the final visual outcomes. Photodynamic therapy (PDT) may be considered a viable adjunct treatment option in such circumstance.

Case report

A 41 year old woman with pathological myopia of −11.0 dioptres in both eyes presented with a subfoveal CNV and subretinal haemorrhage in her right eye in July 2000. The best corrected visual acuity (BCVA) was 5/200 in both eyes. LMT with superotemporal 6 mm scleral imbrication was adopted in treating the CNV recurrence. The CNV however, was still located in the vicinity of the juxtafoveal area and therefore laser photoagulation, bearing the potential risk of late creeping scar, was not suggested. At the 4 months postoperative visit, her left BCVA was 20/200 and the original CNV became more fibrotic with minimal leakage upon fluorescein angiography. Nevertheless, she came back at 5 months with a return of metamorphopsia and a drop in her right vision from 20/200 to 10/200. Dilated fundus examination showed a tiny patch of submacular haemorrhage in direct continuity with the old fibrotic scar (Fig 1A). Fluorescein angiogram demonstrated a fresh recurrent CNV budding out from the original CNV (Fig 1B). Moderate fluorescein leakage could be seen in the late phase (Fig 1C). Treatments comprising revision macular translocation surgery, submacular surgery, photodynamic therapy, and observation had been thoroughly discussed with the patient. In view of minimal invasiveness and comparatively better preservation of surrounding neurosensory retinal tissue, PDT was adopted in treating the CNV recurrence.

PDT with verteporfin infusion and laser delivery was performed in accordance with the standard protocol. After the treatment, the blood clot in the fovea was gradually reabsorbed and the vision improved to 20/200 at 3 months of follow up. Complete regression of the recurrent CNV at the fovea without angiographic leakage was documented over the follow up angiogram at 3 months and subsequently (Fig 1D). The vision remained stable at 20/200 in the latest visit at 24 months after the PDT.

Comment

It has been shown that significant visual improvement may be achieved by LMT for the treatment of subfoveal CNV associated with age related macular degeneration (AMD) or pathological myopia. However, the surgical techniques are demanding and the potential complications are not unusual. One of the late postoperative visually important complications is recurrence of the CNV and this is partially caused by an ineffective translocation of the fovea or a large lesion size of CNV. The incidence of persistent or recurrent CNV after limited LMT has been reported to be 40% and 35% respectively in age related macular translocation and being 21% and 14% respectively in pathological myopia. Not many treatment options are available once the fovea is involved. Viable surgical options including repeated LMT, full 360 degree retinotomy MT, or submacular surgery may be considered but the surgical risk may be inadvertently higher in the reattachment of the neurosensory retina. PDT induces a selective thrombosis of the abnormal CNV and has been proved to be an effective treatment in preventing a significant loss of vision in patients with CNV secondary to AMD or pathological myopia.

Figure 1 Right eye with recurrent myopic CNV after LMT. (A) Fundus photograph of the patient showing the recurrent part of CNV budding from the original one with haemorrhage involving the subfoveal area. (B) Early phase fluorescein (FA), demonstrating the filling of choroidal vascular complex with early hyperfluorescence. (C) Late phase FA showing late moderate fluorescence leakage from the CNV. Photodynamic therapy (PDT) with the size of the laser spot as marked was delivered. (D) Late phase FA at 12 months revealing a complete regression of the recurrent CNV and late scar staining of the original CNV.
Acquired Glanzmann's thrombasthenia causing prolonged bleeding following phacoemulsification

Phacoemulsification under topical anaesthesia is a very rare condition. The patient's recent medical history was significant for recurrent admissions elsewhere for investigation of severe anaemia following gastrointestinal bleeding. The patient described had uncontrollable bleeding for 36 hours following a procedure, which is generally considered to be safe even in patients with a bleeding disorder. She developed bleeding from the conjunctival site where the surgeon grasped the conjunctiva during certain stages of the procedure. One would usually not expect any significant bleeding from this site; however, in a patient with compromised haemostasis the bleeding may be prolonged. Although the bleeding was no more than a gentle ooze at any point in time it was persistent enough for 36 hours before the topical haemostatic material Surgicel had been put to use. The consequences of an intraocular bleed may have seriously threatened her sight.

Figure 1  [A] Conjunctival site immediately after removal of Surgicel. [B] Healed conjunctival bleeding site.

Comment

The patient described had uncontrollable bleeding for 36 hours following a procedure, which is generally considered to be safe even in patients with a bleeding disorder. She developed bleeding from the conjunctival site where the surgeon grasped the conjunctiva during certain stages of the procedure. One would usually not expect any significant bleeding from this site; however, in a patient with compromised haemostasis the bleeding may be prolonged. Although the bleeding was no more than a gentle ooze at any point in time it was persistent enough for 36 hours before the topical haemostatic material Surgicel had been put to use. The consequences of an intraocular bleed may have seriously threatened her sight.

We are not aware of any reports of the use of Surgicel in ophthalmic surgery. All reports of its use are in other fields of surgery. This material is supposed to swell up with blood and form a gelatinous mass that aids in the formation of clot. It acts as a haemostatic adjunct. The exact mode of its action in this patient with antiplatelet antibodies is unclear. Our experience shows that oxidised regenerated cellulose (Surgicel) may have a role in ophthalmic surgery especially in lacrimal and orbital surgery, when faced with bleeding that is difficult to stop. Various cautionary tales associated with use of Surgicel have been reported. Our report suggests that in the presence of a severe bleeding disorder, clear corneal phacoemulsification under topical anaesthesia may not be totally safe. When performing such a procedure in a patient with known bleeding disorder it may be safe to take all the necessary precautions in consultation with a haematologist to avoid a serious bleed that may be sight and life threatening. There may be a role for haemostatic agents like Surgicel.
Correspondence to: S Dinakaran, Department of Ophthalmology, A-Floor, Royal Hallamshire Hospital, Sheffield, UK; sdinakaran@yahoo.com

Accepted for publication 20 January 2003

References


Propionibacterium acnes endophthalmitis diagnosed by microdissection and PCR

Although Propionibacterium acnes, a Gram positive anaerobic bacillus, is the most commonly identified cause of delayed onset postoperative endophthalmitis, routine vitreous cultures are frequently inadequate for its diagnosis. This case describes the utility of the histopathological technique of microdissection and polymerase chain reaction (PCR) for the diagnosis of delayed postoperative endophthalmitis.

Case report

A 78 year old man with a history of vitreous floaters, a coronary bypass, and aortic valve replacement underwent an uncomplicated cataract extraction with intraocular lens (IOL) implantation in the right eye. Three months later, he developed increasing floaters in the right eye and was diagnosed with vitritis unresponsive to corticosteroid treatment. Examination revealed acuities of 20/25 in the right eye and 20/20 in the left with normal intraocular pressures. The right eye was significant for no anterior chamber cells or flare, dilated iris vessels, an IOL without deposits, 3+ vitreous cells with trace haze, and peripheral pigmentary degeneration. The left eye was normal with the exception of trace vitreous cells and a choroidal naevas. A diagnostic vitrectomy was performed in the right eye. A portion of the vitreous specimen was cultured for fungi, aerobic and anaerobic bacteria, and the remainder was processed for cytopathological examination. All cultures for micro-organisms were negative.

The vitreous supernatant and unstained cytology slides were sent to the National Eye Institute for further evaluation. Vitrreal analysis for interleukin 2 (IL-2), IL-4, IL-6, IL-10, IFN-γ, and TNF-α using ELISA (Endogen, Woburn, MA, USA) revealed undetectable cytokine levels. The vitreous slides were stained with Giemsa, Gram, and immunohistochemical stains for T cells, B cells, and macrophages. Cytopathological examination showed clusters of macrophages admixed with CD4+ and CD8+ T cells and B cells (Fig 1A). Gram positive bacilli were seen in the cytoplasm of a few macrophages (Fig 1B). The engulfed bacilli were microdissected under a microscope with a 30 gauge needle and submitted for PCR. Nested PCR with P. acnes specific oligodeoxynucleotide primers complementary to regions of 16S rDNA was used. The primers were Pa1, AAG GCC CTG CTT TGG; Pa2, GCC CCC GCC CAA CCA A; and rPa3, ACT CAC GCT TCG TCA CAG. Nested-PCR analysis revealed P. acnes (Fig 2). A diagnosis of delayed postoperative endophthalmitis was made.

Comment

The most common causes of vitritis in elderly patients are acquired or postoperative infections, sarcoidosis, and intraocular malignancies masquerading as uveitis.1 An early diagnostic procedure is indicated if postoperative endophthalmitis is suspected. In this case, although the chronic inflammation and intracytoplasmic Gram positive bacilli in a few macrophages suggested an infectious process, the negative cultures precluded the diagnosis of an infectious endophthalmitis. To further investigate the possibility of a bacterial infection nested PCR was performed on the microdissected bacilli. Molecular analysis verified the presence of P. acnes and a diagnosis of delayed postoperative endophthalmitis was confirmed.

Vitreous cultures are positive in less than 50% of postoperative endophthalmitis cases. In a study of 23 patients with delayed onset endophthalmitis aqueous culture and microscopy were diagnostic in 0% of cases, vitreous culture was positive in 24% and PCR from the aqueous and vitreous yielded a positive diagnosis in 84% and 92%, respectively.4 Treatment of P. acnes endophthalmitis includes intravitreal vancomycin plus consideration of pars plana vitrectomy with or without capsulectomy with or without IOL removal. Although aggressive surgical intervention eradicates the infection similar visual outcomes are reported with more limited surgical treatment.5

In our case the intracytoplasmic bacteria in the macrophages were the only evidence of a bacterial infection. To detect the presence of P. acnes we referenced the PCR method described by Hykin that used 150 µl of the vitreous for culture and 100 µl for PCR. Using the technique of microdissection and PCR with a similar volume of vitreous we additionally performed cytology and cytokine analysis which are helpful in the diagnosis of other causes of vitritis.6

This case further illustrates the benefits of molecular analysis for the diagnosis of culture
negative delayed onset endophthalmitis. It also describes for the first time microdissection and PCR for the evaluation of endophthalmitis. Advantages of this technique are that it allows for a more comprehensive pathological examination on a limited specimen and provides the option of having the molecular studies being performed elsewhere.

R R Buggage, D F Shen, C-C Chan Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

D G Callanan Texas Retina Associates, Arlington, TX, USA

Correspondence to: Ronald R Buggage, MD, NIH/NEI, Building 10, Room 10N112, Bethesda, MD 20892-1857, USA; baggage@heir.nih.gov

Accepted for publication 21 January 2003

References

Interferon treatment of childhood conjunctival lymphoma

Mucosa associated lymphoid tissue (MALT) lymphoma is the most common ocular adnexal neoplasm. These neoplastic lesions have a more indolent course than non-MALT lymphomas, are usually found in the older age groups (50–70 years), and are usually limited to localised (stage I) disease at presentation, and radiotherapy and chemotherapy have been the mainstay of treatment.1

Case report
A 15 year old male was referred by an ophthalmologist after an 8 month history of unilateral painless follicles at both nasal fornice (Fig 1A). There were no visual sympotms and, based on a working diagnosis of atypical vernal reaction, topical steroid treatment was initiated. The lesions remained static for 3–4 months.

The patient’s visual acuity was 6/4 in both eyes and intraocular pressures measured 15 mm Hg in each eye. Slit lamp examination demonstrated small follicular deposits in both nasal fornice and nasal palpebral conjunctiva. The rest of the ocular examination was unremarkable. Review of systems was negative and the patient’s past medical history and family medical history did not reveal the presence of lymphoproliferative or autoimmune diseases. There were no findings suggestive of Sjögren’s syndrome and physical examination was normal.

The limited amount of biopsy tissue was divided for routine processing and flow cytometry; frozen tissue was therefore unavailable. Histologically a dense lymphoid infiltrate including benign appearing lymphoid follicles was identified (Fig 1B). Lymphoid follicles were surrounded by centrocytic-like cells and small lymphocytes, some of which infiltrated the conjunctival epithelium. Flow cytometry identified a monoclonal B cell population with a CD5–, CD20–, CD10 equivocal phenotype. The histopathological findings in isolation may have represented either an early marginal zone lymphoma or a benign B cell follicular hyperplasia. Absolute distinction on the small amount of tissue was not possible. However, in conjunction with the flow cytometric finding of a monoclonal B cell population, a diagnosis of low grade B cell lymphoma (probably of MALT type) could be made.

Systemic disease was excluded after the following investigations: lumbar puncture; bone marrow aspirate and trephine; CT chest, abdomen, pelvis and sinuses; gallium scan. The patient was subsequently treated with 10 intraläsional injections of 10×10⁶ IU of interferon alfa (IFN-α) over a 4 week period; no side effects were noted during this time. Complete resolution was achieved at 2 months, with no sign of recurrence after 18 months follow up.

Comment
Conjunctival lymphoma is mostly a disease of the elderly, with Shields et al reporting a mean age of diagnosis of 61 years.2 While not a common disease, Akpek et al suggest that its prevalence is higher than previously recognised, and that vigilance is required in patients with chronic ocular irritation and conjunctivitis who do not respond to conventional therapy.3 This is the youngest case of conjunctival lymphoma that we know of in the literature; hence conjunctival lymphoma should be considered in the differential diagnosis of atypical conjunctival lesions in younger patients.

Treatments outlined by Shields et al included radiotherapy (44%), complete excisional biopsy (36%), observation (9%), chemotherapy (6%), and cryotherapy (4%).3

Radiotherapy has been widely used with successful results4 but ocular morbidity in the form of corneal ulcer, radiation induced cataract and ocular lubrication disorders have been reported.5,6 Intralesional IFN-α is a relatively new therapy which has been shown to be both effective and safe in a small number of cases.7,8 Non-sight-threatening ocular complications such as subconjunctival haemorrhage and local chemosis have been reported, as well as minor transient systemic effects including headaches, nausea, fever, chills, and myalgia.9 Administration of intralesional IFN-α is also a relatively simple and quick procedure. It shows great promise as a first line agent to treat conjunctival lymphoma, but long term follow up is needed.

R S Lucas
Department of Ophthalmology, Royal Brisbane Hospital, Herston, Queensland 4029, Australia

R Mortimore
Queensland Medical Laboratory Consulting Pathologists, 60 Ferry Road, West End, Queensland 4101, Australia

T J Sullivan
Department of Ophthalmology, Royal Brisbane Hospital, Herston, Queensland 4029, Australia

M Waldie
Department of Ophthalmology, Royal Brisbane Hospital, Herston, Queensland 4029, Australia

Correspondence to: Associate Professor Timothy John Sullivan, Eyelid, Lacrimal and Orbital Clinic, Department of Ophthalmology, Royal Brisbane Hospital, Herston, Queensland 4029, Australia; tmj@health.qld.gov.au

Accepted for publication 22 January 2003

References
In our experience, this is the first report of corneal anaesthesia being associated with congenital goitre, as the association has not been reported in the literature. The pathophysiology of the corneal anaesthesia and ulceration in this patient is unclear. There are several possible reasons for the corneal anaesthesia. They include herpes simplex keratitis, postoperative anterior segment ischaemia, surgical trauma to the long posterior ciliary nerves or ciliary ganglion, congenital absence of sensation, and surgery reducing Bell's phenomenon.

The clinical course was not typical of herpes simplex and there was no previous history of corneal pathology. Postoperative anterior ischaemic syndrome was unlikely as only two recti muscles were operated on and no evidence of pupillary involvement, which one may expect with trauma to the long posterior ciliary nerves or ciliary ganglion.

Congentinal absence of corneal sensation was the most likely cause, especially in view of his unusual cranial nerve anomalies, and we believe he had pre-existing corneal anaesthesia before squat surgery despite the absence of any other fifth cranial nerve signs. Following the lateral transposition of the superior rectus his Bell's phenomenon was noted to be absent thereby compromising his corneal protection. In addition, he was observed to have significant lagophthalmos while asleep.

We believe that the combination of congenital goitre, abolishment of Bell's phenomenon, and lagophthalmos compromised his corneal integrity resulting in corneal ulceration.

This case highlights the importance of determining corneal sensation before transposition surgery on the superior rectus as Bell's phenomenon may be abolished therefore compromising corneal protection. This is especially relevant in patients with unusual cranial neuropathy and lagophthalmos.

R V Wintle
Eye Unit, Southampton General Hospital, Trema Road, Southampton SO2 5DS, UK

Y F Choong
Eye Unit, University Hospital of Wales, Cardiff, UK

D E Laws
Department of Ophthalmology, Singleton Hospital, Swansea, UK

Correspondence to: Mr Richard V Wintle, Eye Unit, Southampton General Hospital, Trema Road, Southampton SO2 5DS, UK; richardwintle67@yahoo.com

Accepted for publication 16 February 2003

References
1 Pendred V. Deaf mutism and goitre. Lancet 1896;11:532.


The patient continued to make steady progress; 2 months later vision had improved to 6/9 unaided. The patient at that time was troubled by floaters secondary to considerable vitreous debris. At last review in September 2002, visual acuity had further improved to 6/4 with −0.75D sph correction.

Comment
Gemella haemolyans is an aerobic or facultative anaerobic, Gram positive coccus, a normal commensal of the oral cavity and upper respiratory tract of low virulence. A literature search revealed only one previously reported case of infection by Gemella haemolyans, with ketorolac and consecutive endophthalmitis. Interestingly this patient was reported to have active sarcoidosis on presentation, but is now classified as a separate genus within the family Streptococcaceae. No studies on susceptibility to antiseptics have been published, though there is no reason to believe that it may be resistant to povidone-iodine preparations. The organism is stable in vitro to penicillin, streptomycin, vancomycin, chloramphenicol, and tetracyclines.

A recent scientific review of the literature reported that postoperative endophthalmitis is a difficult to identify, because of its close resemblance to viridans streptococci and Neisseria. As diagnostic technology improves, Gemella haemolyans endophthalmitis may be described more often in the future. This report highlights the importance of infection with rare commensal organisms in healthy, immunocompetent individuals after uneventful phacoemulsification cataract surgery.

S V Raman, N Evans, T J Freaggard
Royal Eye Infirmary, Apsley Road, Plymouth, UK

R Cunningham
Department of Microbiology, Derriford Hospital, Plymouth, UK

Correspondence to: S V Raman, West of England Eye Unit, Royal Devon and Exeter Hospital, Exeter, UK; yasoon317@yahoo.com

Accepted for publication 25 February 2003

References


Does topical brimonidine tartrate help NAION?

There is no proved treatment for non-arteritic anterior ischaemic optic neuropathy (NAION). Topical brimonidine tartrate has been reported to have a neuroprotective effect for retinal ganglion cells following experimental elevation of intraocular pressure and optic nerve injury in the rat, which is blocked by coadministration of the α2 antagonist, rauwolfa. Increased retinal ganglion cell survival has also been shown to occur following oral administration of brimonidine in monkeys with experimental glaucoma. These results were the basis of the recently aborted clinical trial of topical brimonidine purite for acute NAION and our retrospective study of 31 patients with NAION, who were evaluated within 3 weeks of the onset of visual loss and followed up for a minimum of 8 weeks. During 2001–2, we treated all (14) patients with brimonidine tartrate within 14 days (mean 3.5, SD 5.52) of the onset of visual loss. Five patients were treated after 1 day of symptoms, 8 were taken four times a day in 11, three times a day in one, and twice a day in two patients. All (17) untreated patients were evaluated the year before and were matched to the treated group for age, sex, cardiovascular risk factors, previous aspirin use, and previous first eye NAION.

Snellem visual acuity and colour vision, using the Ishihara colour plates, were documented and expressed as a decimal equivalent (for acuity: 20/60 = 0.33 and light perception = 0.001; for colour vision: the number of correctly identified plates/the total number of plates). The visual fields (Humphrey or tangent perimetry) were analysed and defects were graded according to the following scale: 0 = normal, 1 = accurate nerve fibre bundle defects, 2 = retinal nerve fibre layer defects (6 degrees), 3 = caecocentral or altitudinal defects, 3 = altitudinal defect plus additional loss, 4 = no light perception. A third examiner, who was unaware of the dates of the visual fields and the patients' treatment status, also evaluated all visual fields and determined, in each patient, whether the field was better or worse than or equivalent to the other field. The intraocular pressure was measured in all (except two) patients. The pressure was 25 mm Hg in one patient in the treated group and 24 mm Hg in one patient in the untreated group.

Statistical analysis of the data involving comparisons of the treated and untreated groups at baseline and 8–12 weeks was performed using the two tailed Wilcoxon signed rank test. The masked examiner's evaluation, the mean visual field (2.0, SD 0.91) was similar to the field (1.93, SD 0.96; p=0.85) for controls. At the 8–12 week examination, the mean visual field grade was 2.15 (SD 0.99) for treated and 1.87 (SD 0.92; p=0.43) for untreated patients. This examiner further found that the outcome visual fields for the treated group were improved in two patients, worsened in six patients (50%), and remained unchanged in four patients. The outcome visual fields for the control group were improved in five patients, worse in two patients (13%), and unchanged in eight patients.

The Wilcoxon signed rank analysis demonstrated that for visual acuity, two patients in the control group and 10 patients in the treated group had negative values or a worse outcome at 8–12 weeks post-treatment. For colour vision, one patient in the control group and eight patients in the treated group had negative values or a worse outcome (p=0.013). For visual fields, one patient in the control group and four patients in the treated group had negative, positive values or a worse outcome at 8–12 weeks (p=0.046).

The average time to start the drops was 3.5 days from the onset of visual loss in those patients who worsened. There was no correlation with a worse outcome and time to initiate therapy.

For all parameters of vision testing, there was a trend for worse visual performance at 8–12 weeks in the group treated with topical brimonidine. Although there was no significant difference for the colour vision outcome, this might reflect that the baseline colour vision value was better for the treated group. The outcome visual field grade was significantly worse in the treated group. The masked examiner's visual field evaluations demonstrated that more treated patients worsened than in the untreated group. When the baseline and outcome of all visual parameters for each individual were compared, the treated group had a significantly worse outcome at 8–12 weeks.

Our results are not the first description of worse outcome in patients treated with α2 agonists for central nervous system ischaemic disease. Studies in animal models and clinical studies in humans suggest the protective effects of drugs, including α2 receptor agonists, may impede recovery following stroke. Clonidine administration caused recurrence of the neurological deficit in animals who had initially recovered. In a recent clinical study, the level of motor recovery of stroke patients was worse in those treated with α2 agonists than in patients not receiving these agents.

Although in experimental optic nerve injury in animal models, brimonidine appears to offer neuroprotection, our results demonstrate that brimonidine tartrate, applied topically up to four times daily, does not appear to be a beneficial treatment for acute NAION.
is possible earlier treatment might have been more effective, although patients who worsened received treatment sooner than those who did not worsen. Increased dosing frequency or using a different preparation of bromidomide might be more effective. Additionally, the number of subjects in the study was small and a negative trend could appear more profound.

H E Fazzone, M J Kupersmith
The Institute for Neurology and Neurosurgery, Beth Israel Medical Center, the New York Eye and Ear Infirmary, New York, USA

J Leibmann
The New York Eye and Ear Infirmary

Correspondence to: Mark J Kupersmith, MD, Department of Neuro-ophthalmology, Room 535, The Institute for Neurology and Neurosurgery, Beth Israel Medical Center, 170 East End Avenue, New York, NY 10128, USA: mkupers@bethisraely.org

Accepted for publication 2 March 2003

References


Chronic eye movement induced pain and a possible role for its treatment with botulinum toxin

Chronic ocular pain may have many causes and can be a frustrating problem for both patient and doctor alike. We describe two patients who had similar symptoms and eye findings who had been unable to relieve their pain with conventional analgesia. We postulate a cause for their pain and describe our experience of a treatment strategy using a standard dose of botulinum toxin injection into an extraocular muscle.

Case 1

A 46 year old white man presented complaining of chronic constant ocular discomfort which followed strabismus surgery 8 years earlier for an A-pattern exotropia with diplopia on downgaze. The pain was worsened by prolonged television watching and prisms in his glasses did not help. Pain was much worse on upgaze and right gaze, which were limited. Oral non-steroidal anti-inflammatory agents (NSAIDs) did reduce the pain a little but only when taken in high doses (100 mg three times daily flurbiprofen).

On examination he had a right hyperphoria, with an A-pattern exotropia and an abnormal head posture for distance. He still had diplopia. Botulinum toxin was injected into his left medial rectus muscle, which resulted in a profound reduction in his symptoms, leaving him with a small exophoria. His diplopia resolved completely after 10 weeks. The “pressure sensation” and pain in the right eye recurred after about 6 months, this time with no diplopia. He had a further injection of toxin 8 months after the first which again significantly improved his pain but gave him diplopia for 3 weeks. He continues to take flurbiprofen 50 mg three times daily orally.

Comment

The pain demonstrated by these two patients is typically much worse in certain directions of gaze and particularly during prolonged gaze holding activities. Ocular muscle ischemia, perhaps caused by constricting scar tissue, remains a possibility but the onset of the pain is very fast making this less likely.

The pain relief seen in our patients may simply be the result of paralyzing an inflamed muscle but there is growing evidence for a separate antinociceptive effect of botulinum toxin. No direct peripheral cutaneous antinoiceptive effect could be shown by Biersch et al.21 however inhibition of release of substance P has been demonstrated in vitro and it can be hypothesised that botulinum toxin treatment may reduce the local release of nociceptive neuropeptides from either cholinergic neurons or from A or C delta fibres in vivo. The mechanisms by which botulinum toxin may relieve pain, including a possible analgesic effect of botulinum toxin metabolites, are reviewed by Guyer.22 There is a growing literature on the use of botulinum for painful conditions, particularly those in which muscle spasm plays a part. These include writer’s cramp, postoperative pain in spastic cerebral palsy, and perhaps more surprisingly, but still found the diplopia intolerable and declined further treatment.

Case 2

A 46 year old white man presented complaining of chronic constant ocular discomfort which followed strabismus surgery 8 years earlier for an A-pattern exotropia with diplopia on downgaze. The pain was worsened by prolonged television watching and prisms in his glasses did not help. Pain was much worse on upgaze and right gaze, which were limited. Oral non-steroidal anti-inflammatory agents (NSAIDs) did reduce the pain a little but only when taken in high doses (100 mg three times daily flurbiprofen).

On examination he had a right hyperphoria, with an A-pattern exotropia and an abnormal head posture for distance. He still had diplopia. Botulinum toxin was injected into his left medial rectus muscle, which resulted in a profound reduction in his symptoms, leaving him with a small exophoria. His diplopia resolved completely after 10 weeks. The “pressure sensation” and pain in the right eye recurred after about 6 months, this time with no diplopia. He had a further injection of toxin 8 months after the first which again significantly improved his pain but gave him diplopia for 3 weeks. He continues to take flurbiprofen 50 mg three times daily orally.

Comment

The pain demonstrated by these two patients is typically much worse in certain directions of gaze and particularly during prolonged gaze holding activities such as when reading or watching television. It had a clear precipitating event and the most remarkable feature is that it had persisted for over 2 years in each case without significant progression or regression. No active disease process may be found to account for the continued pain. The pain is severe and responds only to high doses of analgesics, particularly NSAIDs. None of our patients felt that their pain was satisfactorily controlled by their analgesics.

We believe that there may be a process of chronic low grade inflammation affecting the extraocular muscles and the ocular structures around them which is exacerbated by continued constriction and relaxation of the same muscles. Muscular spasm perhaps triggered by this inflammatory process may be the cause of the most severe pain and this could account for the exacerbations of pain in certain directions of gaze and on prolonged gaze holding activities. Ocular muscle ischaemia, perhaps caused by constricting scar tissue, remains a possibility but the onset of the pain is very fast making this less likely.

The pain relief seen in our patients may simply be the result of paralyzing an inflamed muscle but there is growing evidence for a separate antinociceptive effect of botulinum toxin. No direct peripheral cutaneous antinoiceptive effect could be shown by Biersch et al.21 however inhibition of release of substance P has been demonstrated in vitro and it can be hypothesised that botulinum toxin treatment may reduce the local release of nociceptive neuropeptides from either cholinergic neurons or from A or C delta fibres in vivo. The mechanisms by which botulinum toxin may relieve pain, including a possible analgesic effect of botulinum toxin metabolites, are reviewed by Guyer.22 There is a growing literature on the use of botulinum for painful conditions, particularly those in which muscle spasm plays a part. These include writer’s cramp,23 postoperative pain in spastic cerebral palsy,24 and perhaps more surprisingly, but still found the diplopia intolerable and declined further treatment.

It is not possible to rule out a powerful placebo effect in our patients but, whatever the mechanism of action, their pain was vastly improved and botulinum toxin treatment is very safe in competent hands.

In the cases described botulinum toxin served a dual purpose in that it had the potential to improve their oculard deviation for which it is well known and it also reduced the severe ocular discomfort. Unfortunately, the resulting diplopia limited its usefulness in one case but we feel that this treatment should be considered in this unusual group of patients who present a difficult management problem even to the most experienced ophthalmologists.

B J L Burton, S R Khan, J P Lee
Moorfields Eye Hospital, City Road, London, UK

Correspondence to: John P Lee, Moorfields Eye Hospital, City Road, London, UK; john.lee@moorfields.nhs.uk

Accepted for publication 5 March 2003

References


www.bjophthalmol.com
Intrastromal lamellar femtosecond laser keratoplasty with superficial flap

Lamellar keratoplasty has usually been performed taking a trephine to delineate the extent of the tissue to be excised, and a knife or similar instrument to remove the lamellar corneal tissue from the underlying deep corneal bed. In a similar way, the lamellar donor tissue was prepared and inserted into the recipient bed. The depth of the lamellar excision corresponded to the corneal thickness at the incisional surface to the deep corneal stroma. Marked disadvantages of the technique have been pronounced corneal astigmatism and optical insufficiencies due to the interface between the lamellar graft and the recipient corneal bed caused by irregularities of both surfaces. The purpose of the present report was to describe the new femtosecond laser technology, which may enable us to perform a new type of intrastromal lamellar keratoplasty with preservation of an intact Bowman’s layer and regular corneal epithelium.

Case report

Using a corneal contact lens and a femtosecond laser (20/10 Perfect Vision, AmoBion; 21/1, D-69123 Heidelberg, Germany) with a wavelength of 1060 nm, a spot size of about 10 µm, and a laser pulse duration of several hundred femtoseconds, a pre-descemetal incision running parallel to the corneal surface was created in five postmortem eyes of slaughterhouse pigs. The diameter of the deep stromal incision was 7 mm. In a second step, a circular sagittal incision was performed starting from the peripheral edge of the already existing incision in the pre-descemetal level to the superficial layer of the corneal stroma. In continuation of the latter sagittal incision, the corneal flap was prepared with a diameter of 7 mm, a thickness of about 100 µm, a hinge, and three positional pikes. The pikes in the flap with the corresponding notches in the bed of the flap were formed to increase the rotational stability of the flap after repositioning. The height of the peaks was about 0.40 mm. After opening of the flap the intrastromal segment situated between the pre-descemetal incision and the incision in the superficial stromal level was removed and exchanged against a similar formed flap. This was done to ensure that appropriately aggressive treatment is essential in these patients.

Comment

Femtosecond laser technology allows a new type of intrastromal lamellar keratoplasty with removal of a mid-stromal segment and preservation of an intact Bowman’s membrane. Considering the decreased amount of allogenic corneal tissue transplanted, and regarding the preservation of the original corneal surface, lamellar intrastromal femtosecond laser keratoplasty may be associated with a smaller rate of immunological graft reaction and with a lower postoperative corneal astigmatism in some eyes. Future clinical studies may show whether positional edges in the superficial flap increase its postoperative rotational stability.

Proprietary interest: none

J B Jonas
Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim, Germany; joj Jonas@maaugen uni-heidelberg.de

Accepted for publication 17 March 2003

References


Demographic study of paediatric allergic conjunctivitis within a multiethnic patient population

From October 1999, all patients referred to the paediatric ophthalmology service in Bradford have been added to a computerised database. This is the only paediatric ophthalmology service within the city of Bradford and receives all GP referrals of this type. Patients with a clinical diagnosis of chronic allergic conjunctivitis were identified from October 1999 to July 2001. There were 14 with punctate epithelial erosions (10 Asians and four white children). Comparing patients from both groups with severe disease, there was a relative prevalence of Asians by 6.75 to 1 (Fisher’s test, p<0.001). In two cases, visual loss occurred after the onset of chronic allergic conjunctivitis from epithelial plaque and corneal pannus. Both were Asian.

Comment

Various studies have reported allergic eye disease to be more common among Asian and black patients. This may be due to genetic and environmental factors. We found allergic eye disease to be more common in Asians than white children. It is possible that ocular allergy is multifactorial but perhaps with a greater genetic predisposition in certain ethnic communities. We could not comment on the prevalence of chronic allergic conjunctivitis in the community because of referral bias since we only see patients referred by GPs. The extent to which milder cases are treated in the community is not known but we feel that the more severe cases are the ones referred to our department. Our findings highlight that allergic eye disease appears to be more common and concentrated in Asian patients in the Bradford population. This potential risk of sight threatening disease means that they are more likely to require topical steroid treatment. This has led us to recognise that appropriate aggressive treatment is essential in these patients.

A J Singh, RS K Loh, JA Bradbury
St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
Correspondence to: Mr Anil J Singh, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; mraniljsingh@yahoo.co.uk
Accepted for publication 20 March 2003

References


**CORRECTION**

We wish to apologise for an error in the extended report by Barry and König (Br J Ophthalmol 2003;87:909–16). On p 910 under the heading Orthoptic screening, point four of the bulleted list, line four should have read: “positive”: visual acuity ≥0.4 (10/25).

**NOTICES**

Helping the blind and visually impaired

The latest issue of Community Eye Health (No 45) discusses help for the blind, with an editorial by Sir John Wall of the Royal National Institute for the Blind on the rights of blind people. For further information please contact: Journal of Community Eye Health, International Resource Centre, International Centre for Eye Health, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Kenning Street, London WC1E 7HT, UK (tel: +44 (0)20 7612 7964; email: Anita.Shah@lshtm.ac.uk; website: www.jche.ac.uk). Annual subscription (4 issues) UK£28/US$45. Free developing country applicants.

Second Sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. Details can be found at the charity’s website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

Special Eye Conditions (SPECS)

Special Eye Conditions (SPECS) is a not for profit organisation which acts as an umbrella organisation for support groups of any condition or syndrome with an integral eye disorder. SPECS represents over 50 different organisations related to eye disorders ranging from conditions that are relatively common to very rare syndromes. The website acts as a portal giving direct access to support groups own sites. The SPECS website page is a valuable resource for professionals and may also be of interest to people with a visual impairment or who are blind. For further details about SPECS contact: Kay Parkinson, SPECS Development Officer (tel: +44 (0)1803 524238; email: k@eyeconditions.org.uk; website: www.eyeconditions.org.uk).

The British Retinitis Pigmentosa Society

The British Retinitis Pigmentosa Society (BRPS) was formed in 1975 to bring together people with retinitis pigmentosa and their families. The principle aims of BRPS are to raise funds to support the programme of medical research into finding a cure for this hereditary disease, and through the BRPS welfare service, help members and their families cope with the everyday concerns caused by retinitis pigmentosa. Part of the welfare service is the telephone help line (+44 (0)1280 860 363), which is a useful resource for any queries or worries relating to the problems that retinitis pigmentosa can bring. This service is especially valuable for those recently diagnosed with retinitis pigmentosa, and all calls are taken in the strictest confidence. Many people with retinitis pigmentosa have found the Society helpful, providing encouragement, and supporting them with the Help line, the welfare network and the BRPS branches throughout the UK (tel: +44 (0)1280 821 334; email: lynda@brps.demon.co.uk; website: www.brps.demon.co.uk).

Surgical Eye Expeditions International

Volunteer ophthalmologists in active surgical practice are needed to participate in short term, sight restoring eye surgery clinics around the world. Contact: Harry S Brown, Surgical Eye Expeditions International, 27 East De La Guerra, C-2, Santa Barbara, CA 93101–9588, USA (tel: +805 963 3303; fax: +805 965 3564; email: hsbrown.md@cox.net or seeinl@seeinl.org; website: www.seeinl.org)

Rise in organ transplant numbers

According to UK Transplant, the UK has seen the highest number of organ transplants in six years in 2003. From 8 303 to 31 March (2003) 2777 patients had their lives saved or dramatically improved through the generosity of 1064 donors. This equated to a 6% increase compared to the previous 12 months (1 April 2001 to 31 March 2002). Furthermore during 2002–3, the highest number of people benefited from a cornea transplant for five years (1997–98) and 240 more people had their sight restored than the previous year. For further information see UK Transplant’s website (www.uktransplant.org.uk).

Elimination of avoidable blindness

The 56th World Health Assembly (WHA) considered the report on the elimination of avoidable blindness (doc A56/26) and urged Member States to: (1) Commit themselves to supporting the Global Initiative for the Elimination of Avoidable Blindness by setting up a national Vision 2020 plan by 2005; (2) Establish a national coordinating committee for Vision 2020, or a national blindness prevention committee to help implement the plan; (3) Implement the plan by 2007; (4) Include effective monitoring and evaluation of the plan with the aim of showing a reduction in the magnitude of avoidable blindness by 2010; (5) To support the mobilisation of resources for eliminating avoidable blindness. The WHA also urged the Director-General to continue and strengthen WHO’s collaboration with Member States and the partners of the Global Initiative for the Elimination of Avoidable Blindness as well as in the coordination and support of national capability.

MSc course in Community Eye Health

The International Centre for Eye Health is offering a full time MSc course in Community Eye Health from 29 September 2003 to 19 September 2004. The course is not clinical and is specifically for eye health professionals wanting to work in the field of community eye health. The course is designed in keeping with the aims, priorities, and strategies of Vision 2020—the Right to Sight. The course costs £3939 for home students and £14 110 for overseas students. Further information in the Registry, 50 Bedford Square, London WC1B 3DP, UK (tel: +44 (0)20 7927 2239; fax: +44 (0)20 7323 0638; email: Adrienne.Burrough@lshtm.ac.uk; website: www.lshtm.ac.uk).

Ophthalmic Anesthesia Society (OAS)—17th Scientific Meeting

The 17th Scientific Meeting of the Ophthalmic Anesthesia Society (OAS) will be held 3–5 October 2003 at the Westin Michigan Avenue Chicago, Chicago, USA. Programme co-chairs: Marc Allen Feldman MD MHS and Steven T Charles MD. The CME joins Cleveland Clinic Foundation; CME hours are pending. Fees for OAS members are $300; non-members $475; students $50. Further details: OAS, 793-A Foothill Blvd, PMB 119, San Luis Obispo, CA 93405 USA (tel: +1 805 534 0300; fax: +1 805 534 9030; email: info@eyeanesthesia.org; website: www.eyeanesthesia.org)

Glaucoma Society 24th Annual Meeting and Dinner

The Glaucoma Society 24th Annual Meeting and Dinner will take place on 20 November 2003 at the College of Physicians, London, UK. Further details: Ms Janet Flowers (email: glauosc@ukiere.freeserve.co.uk).

Detachment Course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding the Annual Meeting of Iranian Society of Ophthalmology

The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding Annual Meeting of Iranian Society of Ophthalmology will be held...
on 29–30 November 2003 and 1–4 December 2003 respectively, at the Razi Conference Center, Hemmat Hyw, Tehran, Iran. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleichstr. 12, Breuningerbau, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de). Local organisation: Dr Arman Masheiekhi, Dr Siamak Moradian, Dept of Ophthalmology, Labbanfinejad Medical Center, Pasdaran Ave, Boostan 9, Tehran, 16666, Iran (fax: +98 21 254 9039; email: labbafi@hotmail.com).

5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT)

The 5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) will take place 11–14 March 2004, in Monte Carlo, Monaco. Please visit our website for details of the scientific programme, registration, and accommodation. To receive a copy of the Call for Abstracts and registration brochure please submit your full mailing details to http://www.kenes.com/isopt/interest.htm.


XVth Meeting of the International Neuro-Ophthalmology Society